Provided herein are oligosaccharide compositions for administration to animals suitable for improving animal health, including, for example, to treat diseases or disorders or to enhance animal growth.

The present invention relates to compositions comprising a mix of human milk oligosaccharides consisting of 2′-fucosyllactose and difucosyllactose, for use in the reduction of pain and/or perception of pain in an infant or in a young child. The compositions are particularly effective in the restoration of the sensitivity of the bi-directional pain transmission pathways in the gut-brain axis to normal levels. The compositions are in particular useful in reducing abdominal pain, such as pain associated with gastrointestinal discomfort, functional gastrointestinal disorders, and/or gastrointestinal diseases and consequently also contribute to reducing the crying periods and to improving the quality of sleep, the general quality of life, the mood, the playfulness, the temperament and/or the happiness of the infants and young children.

The present invention relates to compositions comprising a mix of human milk oligosaccharides consisting of 2′-fucosyllactose and difucosyllactose, for use in the reduction of pain and/or perception of pain in an infant or in a young child. The compositions are particularly effective in the restoration of the sensitivity of the bi-directional pain transmission pathways in the gut-brain axis to normal levels. The compositions are in particular useful in reducing abdominal pain, such as pain associated with gastrointestinal discomfort, functional gastrointestinal disorders, and/or gastrointestinal diseases and consequently also contribute to reducing the crying periods and to improving the quality of sleep, the general quality of life, the mood, the playfulness, the temperament and/or the happiness of the infants and young children.

Compositions and methods are described herein that can reduce the frequency and/or severity of gastroesophageal reflux disease (GERD). Such compositions and methods can include use of maltosyl-isomaltooligosaccharides with or without one or more proton pump inhibitors, one or more potassium-competitive acid blockers, one or more H-2 antagonists, one or more antiacids, one or more bile acid sequestrants, one or more prokinetic agents, one or more dopamine receptor antagonists, one or more coating agents (protectants), one or more antibiotics, one or more probiotics, or a combination thereof.

Compositions and methods are described herein that can reduce the frequency and/or severity of gastroesophageal reflux disease (GERD). Such compositions and methods can include use of maltosyl-isomaltooligosaccharides with or without one or more proton pump inhibitors, one or more potassium-competitive acid blockers, one or more H-2 antagonists, one or more antiacids, one or more bile acid sequestrants, one or more prokinetic agents, one or more dopamine receptor antagonists, one or more coating agents (protectants), one or more antibiotics, one or more probiotics, or a combination thereof.

Compositions and methods are described herein that can reduce the frequency and/or severity of gastroesophageal reflux disease (GERD). Such compositions and methods can include use of maltosyl-isomaltooligosaccharides with or without one or more proton pump inhibitors, one or more potassium-competitive acid blockers, one or more H-2 antagonists, one or more antiacids, one or more bile acid sequestrants, one or more prokinetic agents, one or more dopamine receptor antagonists, one or more coating agents (protectants), one or more antibiotics, one or more probiotics, or a combination thereof.

The invention relates to the field of nutritional ingredients, in particular to methods for producing hypoallergenic galacto-oligosaccharides (GOS) and the use thereof in food and drink items. Provided is the use of a beta-galactosidase (EC 3.2.1.23) derived from Cryptococcus terrestris (recently renamed Papiliotrema terrestris) in the production of a hypoallergenic GOS preparation having a reduced capacity to induce an allergic response in a subject.

The invention relates to the field of nutritional ingredients, in particular to methods for producing hypoallergenic galacto-oligosaccharides (GOS) and the use thereof in food and drink items. Provided is the use of a beta-galactosidase (EC 3.2.1.23) derived from Cryptococcus terrestris (recently renamed Papiliotrema terrestris) in the production of a hypoallergenic GOS preparation having a reduced capacity to induce an allergic response in a subject.

Described herein are food ingredients made up of oligosaccharide compositions, and methods of producing such food ingredients, as well as methods of using such food ingredients in food products. The present application addresses this need in the art by providing oligosaccharide compositions that have similar physical characteristics to commercially available carbohydrate sources, such as fiber, but lower metabolic energy. Methods of producing such oligosaccharide compositions suitable for use in food products are also provided herein.

A synergistic combination of butyric-acid-producing prebiotics and probiotics, which is used in the fields of foods, dietary supplements and drugs. Specifically, a composition containing probiotics and prebiotics, a food, dietary supplement or pharmaceutical preparation including the composition, and the use of the composition for alleviating and improving a disease or a discomfort, or reducing the occurrence of a disease or a discomfort, wherein the disease or discomfort is related to insufficient butyric acid in the intestine, or to insufficient butyric-acid-producing microorganisms in the intestine. A method for promoting Bifidobacterium lactis HNO19 to produce butyric acid, the method including using a galactooligosaccharide and lactulose as carbon sources for the cultivation of Bifidobacterium lactis HNO19, wherein the weight ratio of the galactooligosaccharide to lactulose is 1:1 to 4:1.